Melvin Lee Kiang Chua, MD, PhD
Dr Melvin L.K. Chua is a Clinician-Scientist, and Principal Investigator of the Precision Radiation Oncology Programme, Division of Radiation Oncology. He is supported by the National Medical Research Council Clinician-Scientist Award. Dr Chua’s research is focused on precision medicine using prognostic and predictive biomarkers for experimental therapeutics in the management of prostate and nasopharyngeal cancers. He is an active trialist, and is the lead PI for several Phase II and III clinical trials in nasopharyngeal cancer. Dr. Chua serves on several editorial boards, notably as Editor-in-Chief, Annals of Nasopharynx Cancer; and he is the Associate Senior Editor for the Head and Neck Cancer Section of the Red Journal – the official journal for the American Society of Radiation Oncology. He is an active member on the ASCO International working groups, including serving on the International Education Steering Group and the ASCO Asia Pacific Regional Council, and is affiliated with ASCO, AACR, ASTRO, ESMO and ESTRO. Dr. Chua has spoken at over 100 scientific symposiums, and has published over 80 peer-reviewed papers, including high-impact articles in the New England Journal of Medicine, The Lancet, Nature, Cell, and Journal of Clinical Oncology.
Dr. Chua a Clinician-Scientist at the National Cancer Centre Singapore (NCCS) and the Duke-NUS Medical School. He is the Head of Department and Senior Consultant for the Department of Head and Neck and Thoracic Radiation Oncology, Principal Investigator of the Precision Radiotherapeutics and Oncology Programme (PROP) (www.chualabnccs.com); and Director of the Data and Computational Science Hub at NCCS. He is currently Associate Professor (On Tenure) of Duke-NUS Medical School, Singapore; and Visiting Professor of the Zhongnan Hospital of Wuhan University, China. His key research focus areas are: (1) Developing a comprehensive nasopharyngeal carcinoma clinical and translational research programme that leverages on innovative designs of phase 2-3 trials, a multi-dimensional, deeply-annotated clinical-molecular database, coupled with broad-scale computational genomics approaches for biomarker discoveries; and (2) A translational radiation research programme that leverages on bench-to-bedside expertise to understand the mechanistic pathways of radiation resistance, and to develop new treatment regimens to target these molecular vulnerabilities. Among his main accomplishments are: (1) Developing the ASCO-CSCO international guidelines on the treatment of locoregionally-advanced nasopharyngeal carcinoma; (2) Co-Lead Investigator of several randomised controlled trials that changed the standard of care treatments in nasopharyngeal carcinoma; (3) Lead Investigator of Singapore Nasopharyngeal Carcinoma Large Collaborative Grant Program; and notably, (4) Chair of the Nasopharyngeal Carcinoma Expert Panel for the American Joint Committee on Cancer and Union for International Cancer Control TNM-Staging 9th version.
Disclosures:
- Employment: National Cancer Centre Singapore:Clinician-Scientist:Employee
- Compensation: Janssen: Advisory Board, Advisory Board Type, Advisory Board Proprietary-End Date: to present ;MSD: Advisory Board, Advisory Board Type, Advisory Board Proprietary-End Date: to present ;ImmunoSCAPE: Consultant-End Date: to present ;IQVIA: Consultant-End Date: to present ;Telix Pharmaceutical: Consultant-End Date: 2022 ;PVMed: In-kind Donations-End Date: to present ;Decipher Bioscience: Grant Research Funding-End Date: to present ;Astellas: Speaker's Bureau-End Date: to present ;AstraZeneca: Spea
- Ownership: High Sensitivity Lateral Flow Immunoassay For Detection of Analyte in Samples (10202107837T), Singapore:Copyright;Digital Life Line:Stock
- Leadership: Alice's Arc:Trustee;ASCO:International Education Steering Group;ASCO:Asia-Pacific Regional Council Member